Femal Sexual Arousal Disorder (FSAD) Treatment Study
A Phase 2, Randomized, Double-blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of Estetrol in Postmenopausal Subjects with Female Sexual Arousal Disorder
- Sex at Birth: Female
- Age: Adult (18 - 64)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied:
Study Purpose
The purpose of this study is to determine if an investigational treatment may improve some of the symptoms associated with Female Sexual Arousal Disorder (FSAD) in postmenopausal women (who have had a hysterectomy), such as vaginal dryness and swelling and genital pain that occurs just before, during or after sexual intercourse. The treatment part of the study will last 12 weeks (84 days). The total study participation time may be up to 30 weeks.
Who Can Participate
Women 40-65 years old with FSAD may be eligible for this study.
Locations
UH Landerbrook Health Center
5850 Landerbrook Drive
Mayfield Heights OH, 44124
UH Ahuja Medical Center
3999 Richmond Road
Beachwood OH, 44122
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: STUDY20240226
- StudyID: 2023-01373
- ClinicalTrials.gov: N/A
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422